Discontinuation of Prophylaxis against<i>Mycobacterium avium</i>Complex Disease in HIV-Infected Patients Who Have a Response to Antiretroviral Therapy
Wafaa El‐Sadr(Columbia University Irving Medical Center), Fred M. Gordin, Ana Martı́nez(Consejo Superior de Investigaciones Científicas), Lisa Bjorling Grant(University of Minnesota), Sharon Mannheimer(Columbia University Irving Medical Center), Barbara Gallagher(Philadelphia Fight), Lawrence R. Crane(Wayne State University), William J. Burman(Case Western Reserve University), Doug Zeh(Media Working Group), John P. Matts(University of Minnesota), Richard Hafner(National Institutes of Health)
Cited by 156
Related Papers
Cardiovascular disease risk factors in HIV patients – association with antiretroviral therapy. Results from the DAD study
|AIDS|2003|987
Trends in underlying causes of death in people with HIV from 1999 to 2011 (D:A:D): a multicohort collaboration
|The Lancet|2014|930
Risk of Myocardial Infarction in Patients with HIV Infection Exposed to Specific Individual Antiretroviral Drugs from the 3 Major Drug Classes: The Data Collection on Adverse Events of Anti‐HIV Drugs (D:A:D) Study
|The Journal of Infectious Diseases|2009|649
COVID-19: Drug Targets and Potential Treatments
|Journal of Medicinal Chemistry|2020|469